The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gray JE, Schenker M, Nahit Şendur MA, Leonova V, Kowalski D, Kato T, Orlova R, Chih-Hsin Yang J, Langleben A, Pilz A, Ungureanu A, Mak MP, Flavia De Angelis, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM.
Gray JE, et al. Among authors: shamoun m.
J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435-3. doi: 10.1016/j.jtho.2024.10.026. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 39521434
Free article.